---
title: "What investors don’t understand about Abbott Laboratories"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292900985.md"
description: "Abbott Laboratories is underpriced as investors view it merely as a slow-growth dividend stock, ignoring its strategic pivot. Key growth drivers include the FreeStyle Libre CGM franchise with significant untapped market potential and the $21B acquisition of Exact Sciences to launch a Cancer Diagnostics unit. Despite recent stock declines, Abbott maintains strong financial performance with consistent earnings beats and dividend increases, suggesting a disconnect between market perception and fundamental value."
datetime: "2026-07-16T11:55:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292900985.md)
  - [en](https://longbridge.com/en/news/292900985.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292900985.md)
---

# What investors don’t understand about Abbott Laboratories

Quick ReadAbbott trades at 17x forward earnings with shares 29% below the analyst consensus buy target, yet the company has posted four consecutive EPS beats.Despite DexCom competition, CEO Robert Ford sees the global CGM market growing from 12 million to 80 million users, anchored by FreeStyle Libre.Abbott's $21 billion Exact Sciences acquisition ...

### Related Stocks

- [EXAS.US](https://longbridge.com/en/quote/EXAS.US.md)
- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)
- [DXCM.US](https://longbridge.com/en/quote/DXCM.US.md)

## Related News & Research

- [23:20 ETPRIVACY ALERT: Abbott Laboratories and Exact Sciences Corporation Under Investigation for Data Breach of Patient Records](https://longbridge.com/en/news/293695963.md)
- [Abbott wins dismissal of shareholder lawsuit over 2022 infant formula recall](https://longbridge.com/en/news/293792909.md)
- [Abbott investigates two separate cyber incidents, says no operations affected](https://longbridge.com/en/news/293079773.md)
- [Key facts: Abbott completes TECTONIC IVL; closes Exact; raises guidance](https://longbridge.com/en/news/292999283.md)
- [These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results](https://longbridge.com/en/news/293046426.md)